T2 Biosystems Announces Customer Presentations at October Conferences
LEXINGTON, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced upcoming scientific presentations that will be made by users of T2Direct Diagnostics™ at leading conferences in October.
At IDWeek 2018 Conference in San Francisco, held October 3-7, 2018, there will be multiple scientific poster and in-booth presentations on the T2Bacteria® and T2Candida® Panels. Presentations will include clinical experience with the FDA-cleared T2Bacteria and T2Candida Panels by clinicians from Denver Health, Henry Ford Health System, Lee Health System, and the University of Pittsburgh.
“Sepsis is a huge issue that every hospital faces. With the objective of alleviating the uncertainty around sepsis, we evaluated the impact of the T2Bacteria Panel and the T2Dx Instrument,” said Mitchell J. Cohen, M.D., Bruce Rockwell Distinguished Chair of Trauma Surgery, Denver Health Medical Center and Professor and Vice Chair of Surgery at the University of Colorado. “Our results, which we are reporting here at IDWeek, suggest that as a culture-independent diagnostic test, T2Bacteria Panel results were both clinically actionable and available days earlier than the blood culture-based test results.”
The Company will also present at a plenary session at the World Antimicrobial Resistance Congress, October 25-26, 2018, in Washington, DC. Speakers Cornelius J. Clancy, Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program, University of Pittsburgh, and Mary Millard, M. Ed, Patient Advocate and Sepsis Survivor will be presenting with T2 Biosystems’ Chief Scientific Officer Thomas J. Lowery, Ph.D.
“The October conferences provide an exciting opportunity for the Company and our customers to highlight the benefits of the T2Bacteria and T2Candida Panels,” said John McDonough, president and chief executive officer. “The data continue to show our technology provides faster detection and the potential to begin targeted therapy sooner, as compared to blood culture-based diagnostics. We look forward to raising awareness of T2Direct Diagnostics at these meetings.”
IDWEEK IN-BOOTH PRESENTATIONS
TITLE: Overview and Analysis of Trial Data Supporting FDA-clearance of the T2Bacteria Panel Presenter: Cornelius J. Clancy, M.D., Associate Professor of Medicine, Infectious Diseases Division and Director, Mycology Program, University of Pittsburgh Time: October 4, 1:00 p.m. PTLocation: Booth #413
TITLE: Can We De-escalate? Early T2Bacteria Panel Data from Lee HealthPresenter: Sandy Estrada, Pharm.D., BCPS, Director, Clinical Affairs, T2 BiosystemsTime: October 4, 1:30 p.m. PT; October 5, 1:00 p.m. PTLocation: Booth #413
TITLE: Tales from the Trenches – The Impact of T2Candida at Henry Ford in Transplant Patient Management Presenter: Zohra Chaudhry, M.D., Infectious Diseases Fellow, Henry Ford Hospital Time: October 4, 3:30 p.m. PT Location: Booth #413
TITLE: Identification in Hours, Targeted Therapy Today: The Impact of Truly “Direct from Sample” Laboratory Diagnostics Presenter: Thomas J. Lowery, Ph.D., Chief Scientific Officer, T2 Biosystems Time: October 5, 10:00 a.m. PT Location: Booth #413
IDWEEK POSTER PRESENTATIONS
TITLE: Novel T2Candida Panel Assay Compared to Blood Cultures for Detection of Candidemia in Transplant and Non-Transplant Patients Session: Poster Abstract Session: Fungi and Parasites in Immunocompromised PatientsPoster Number: #1134Presenter: Noman Hussain, M.D., Infectious Diseases, Henry Ford Health SystemTime: October 5, 12:30 p.m. PTLocation: S Poster Hall
TITLE: Implementation of the T2 Biosystems T2Bacteria Panel in a Level-One Trauma Center, Safety Net Hospital Session: Poster Abstract Session: Diagnostics: Bacteria and MycobacteriaPoster Number: #2006Presenter: Caitlin Robinson, B.S., Surgery, Denver Health and Hospital AuthorityTime: October 6, 12:30 p.m. PTLocation: S Poster Hall
TITLE: Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A successful pilot study of diagnostic stewardship (DS) directed toward specific intensive care unit (ICU) patients (pts) at-risk for sepsis due to invasive candidiasis (IC) Session: Poster Abstract Session: Diagnostics: Mycology Poster Number: #2033 Presenter: Ryan K. Shields, Pharm.D., University of Pittsburgh, School of Medicine Time: October 6, 12:30 p.m. PT Location: S Poster Hall
TITLE: Impact of T2 Candida Panel on Species Specific Anti-fungal De-escalation Session: Poster Abstract Session: Diagnostics: Mycology Poster Number: #2041 Presenter: Zohra Chaudhry, M.D., Henry Ford Hospital Time: October 6, 12:30 p.m. PT Location: S Poster Hall
TITLE: T2-Candida (T2MR) versus Beta-D-Glucan (BDG) for Preemptive Antifungal Stewardship in the Intensive Care Unit (ICU) Session: Poster Abstract Session: Diagnostics: Mycology Poster Number: #2043 Presenter: Christian Gill, Pharm.D., Henry Ford Hospital Time: October 6, 12:30 p.m. PT Location: S Poster Hall
WORLD ANTIMICROBIAL RESISTANCE CONGRESS PRESENTATIONS
TITLE: Antimicrobial Therapy for Life-Threatening Infections: Speed is Life – the Devastation of a Delayed Diagnosis
-- We think we know, but do we? What really are the true costs of sepsis? – Mary’s Story, a 360 degree view -- Earlier targeted antibiotic therapy with T2MR technology: It can be done -- Utilizing same-day sepsis pathogen ID for faster therapy, enhanced stewardship, improved outcomes in practice
Session Type: Keynote AddressPresenters:
-- Cornelius J. Clancy, M.D. Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program, University of Pittsburgh -- Mary Millard, M. Ed, Patient Advocate, Sepsis Survivor -- Thomas J. Lowery, Ph.D. Chief Scientific Officer, T2 Biosystems
Time: October 26, 9:20 a.m. ET
TITLE: Catch 22 - Antimicrobial Stewardship: Reports, Penalties, and Payers, Oh My!Session Type: Executive RoundtablePresenter: Sandy Estrada, Pharm.D., BCPS, Director, Clinical Affairs, T2 BiosystemsTime: October 25, 2:30 p.m. ET
About T2 Biosystems:T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida Panel, and T2Bacteria Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Media Contact: Gina Kent, Vault Communicationsgkent@vaultcommunications.com610-455-2763
Investor Contact: Matthew Clawson, W2O Groupmclawson@w2ogroup.com949-370-8500